Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1503-1511

  Lin, T C ^a,c   Yang, C Y ^a,b   Kao Yang, Y H ^a,c   Lin, S J ^c,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alendronate; Osteonecrosis of the jaw; Osteoporosis; Pharmacoepidemiology

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CEPHALOSPORIN; CLINDAMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALOXIFENE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; JAW OSTEONECROSIS; MALE; OSTEOPOROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SPINE FRACTURE; TAIWAN; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RALOXIFENE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TAIWAN;

EID: 84899660693     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2624-6     Document Type: Article

References (31)

1. Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. [Review] [60 refs]. Am J Med 122(2 Suppl):S33-S45
2. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F et al (2009) Bisphosphonate associated osteonecrosis of the jaw. [Review] [95 refs]. J Rheumatol 36(3):478-490
3. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115-1117
4. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144(10):753-761
5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527-534
6. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11):1567-1575
7. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N (2013) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int 24(1):237-244
8. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral Maxillofacial, Surgeons (2007) Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369-376
9. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. [see comment]. J Natl Cancer Inst 99(13):1016-1024
10. Cartsos VMZS, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes. J Am Dent Assoc 139:23-30
11. Pazianas M, Blumentals WA, Miller PD (2008) Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int 19(6):773-779
12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. [see comment]. N Engl J Med 356(18):1809-1822
13. NHIRD. National Health Insurance Research Database, Taiwan. http://www.nhri.org.tw/nhird/en/index.htm. Assessed Jan. 4th, 2011
14. Lin TC, Yang CY, Kao Yang YH, Lin SJ (2011) Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 90(1):109-116
15. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. [Review] [57 refs]. Am J Med 121(6):475-483
16. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Assessed Jan. 4th, 2011
17. Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26(5):546-550
18. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. [see comment]. Mayo Clin Proc 81(8):1013-1022
19. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu MM et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-836
20. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C et al (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. [Review] [69 refs]. Lancet Oncol 9(12):1166-1172
21. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68(2):243-253
22. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21(8):810-817
23. Van den Wyngaert T, Huizing MT, Vermorken JB (2007) Osteonecrosis of the jaw related to the use of bisphosphonates. [Review] [60 refs]. Curr Opin Oncol 19(4):315-322
24. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM et al (2010) Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int 21(5):847-853
25. King AE, Umland EM (2008) Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. [Review] [71 refs]. Pharmacotherapy 28(5):667-677
26. Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ et al (2011) ONJ in two dental practice-based research network regions. J Dent Res 90(4):433-438
27. Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS (2011) Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Ann Pharmacother 45(10):1199-1206
28. Zavras AI, Zhu S (2006) Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? [see comment]. J Oral Maxillofac Surg 64(6):917-923
29. American Association of Oral and Maxillofacial Surgeons (2007) Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369-376
30. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. [Review] [57 refs]. Mayo Clin Proc 82(12):1493-1501
31. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414-2419